title: Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
abstract: Treatment of superficial bladder carcinoma in situ with Connaught BCG (ImmuCyst) significantly increased complete response rate and extended the disease-free interval when compared with Doxorubicin (DOX) chemotherapy. In 54 patients treated with ImmuCyst, 74% showed complete response compared with 42% of 60 patients treated with DOX. The median disease-free time was 48.2 months for BCG and 5.9 months for DOX treatment. Types and severity of adverse reactions were similar for both treatments and within tolerable ranges.
authors.affiliation: Connaught Laboratories Limited, Willowdale, Ontario, Canada.
authors.forename: L
authors.initials: L
authors.lastname: Barreto
authors.forename: Z
authors.initials: Z
authors.lastname: Csizer
authors.forename: J D
authors.initials: JD
authors.lastname: Sparkes
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005334:Fever / Q000209:etiology; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009378:Neoplasms, Multiple Primary / Q000401:mortality; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D014570:Urologic Diseases / Q000209:etiology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001500:BCG Vaccine; D014613:Vaccines, Attenuated; D004317:Doxorubicin